Study register · detail
Mixed
GRADE
Moderate
248 citations
Samplen = 15 Pat.
Duration3 separate occasions
ControlPlacebo
EndpointBOLD response
Blindingdoppelblind
DesignRCT
Cannabinoidkombination
Max. dose610.0 mg
Routeoral
Key finding
Δ9-THC increased psychotic symptoms, anxiety and sedation, modified brain activation in the parahippocampus and ventrostriatum, but did not significantly impair learning performance; cannabidiol showed no such effects.
Summary
n=15 healthy subjects, THC-induced modulation of mediotemporal and ventrostriatal function using fMRI; THC modulated activity in the hippocampus and ventral striatum, regions relevant to psychosis pathophysiology.
P
PopulationHealthy male adults (English-speaking, right-handed, white) with minimal cannabis exposure (≤15 occasions), n=15
I
InterventionΔ9-Tetrahydrocannabinol (10 mg oral) and cannabidiol (600 mg oral), each as a single dose
C
ControlPlacebo
O
OutcomeΔ9-THC significantly increased psychotic symptoms, anxiety and intoxication; enhanced parahippocampal activation during encoding (Blocks 2+3) and attenuated ventrostriatal activation during retrieval (correlated with psychosis symptoms). Cannabidiol showed no significant effects. Verbal learning performance unchanged.
Confidence in the evidence
Moderate
The third of four GRADE levels, the effect estimate is probably reliable.
Downgraded for
Imprecision
Quality profile
Sample size
★★★★★
Blinding
Double-blind
Effect size
Mixed
Citations / year
★★★★★
Authors
Share
Abstract
Context: Cannabis sativa use can impair verbal learning, provoke acute psychosis, and increase the risk of schizophrenia. It is unclear where C. sativa acts in the human brain to modulate verbal learning and to induce psychotic symptoms.
Objectives: To investigate the effects of 2 main psychoactive constituents of C. sativa, Delta9-tetrahydrocannabinol (Delta9-THC) and cannabidiol, on regional brain function during verbal paired associate learning.
Design: Subjects were studied on 3 separate occasions using a block design functional magnetic resonance imaging paradigm while performing a verbal paired associate learning task. Each imaging session was preceded by the ingestion of Delta9-THC (10 mg), cannabidiol (600 mg), or placebo in a double-blind, randomized, placebo-controlled, repeated-measures, within-subject design.
Setting: University research center.
Participants: Fifteen healthy, native English-speaking, right-handed men of white race/ethnicity who had used C. sativa 15 times or less and had minimal exposure to other illicit drugs in their lifetime.
Main Outcome Measures: Regional brain activation (blood oxygen level-dependent response), performance in a verbal learning task, and objective and subjective ratings of psychotic symptoms, anxiety, intoxication, and sedation.
Results: Delta9-Tetrahydrocannabinol increased psychotic symptoms and levels of anxiety, intoxication, and sedation, whereas no significant effect was noted on these parameters following administration of cannabidiol. Performance in the verbal learning task was not significantly modulated by either drug. Administration of Delta9-THC augmented activation in the parahippocampal gyrus during blocks 2 and 3 such that the normal linear decrement in activation across repeated encoding blocks was no longer evident. Delta9-Tetrahydrocannabinol also attenuated the normal time-dependent change in ventrostriatal activation during retrieval of word pairs, which was directly correlated with concurrently induced psychotic symptoms. In contrast, administration of cannabidiol had no such effect.
Conclusion: The modulation of mediotemporal and ventrostriatal function by Delta9-THC may underlie the effects of C. sativa on verbal learning and psychotic symptoms, respectively.
The impediment to action advances action.